供者外周血干细胞输注预防高危白血病单倍型移植后复发的临床研究  

The effects of donor peripheral blood stem cell infusion in the prevention of relapse in high risk leukemia after haplotype hematopoietic stem cell transplantation

作　　者：张媛[1] 陈惠仁[1] 刘晓东[1] 何学鹏[1] 楼金星[1] 郭智[1] 

机构地区：[1]北京军区总医院血液科,100700

出　　处：《中华内科杂志》2011年第6期492-495,共4页Chinese Journal of Internal Medicine

摘　　要：目的 探讨供者粒细胞集落刺激因子（G-CSF）动员外周血干细胞输注对高危复发白血病患者单倍型移植后白血病复发的预防作用,评价其疗效及安全性.方法 对20例复发未缓解白血病患者在单倍型造血十细胞移植（HSCT）后给予预防性外周血干细胞输注,供者接受G.CSF 5～10μg·kg-1·d-1,分次注射,第5天采集外周血干细胞,在移植90 d后（＋90 d）行第1次输注,30 d后4例患者行第2次输注,除1例第1次输注的单个核细胞数（MNC）为0.1×108个/kg外,其他患者均为0.2×108个/kg.外周血千细胞输注后观察移植物抗宿主病（GVHD）的发生、白血病复发率及患者长期生存的情况.结果 外周血干细胞输注后,中位随访25（4～印）个月,19例患者发生急性GVHD,其中Ⅲ度以上4例,累积发生率22.9%,均是接受2次输注的患者;可以评价的慢性GVHD13例,其中10例为局限性慢性GVHD.无患者因GVHD死亡.9例患者复发死亡,其余11例患者无病生存,其中4例慢性髓性白细胞、4例急性髓性白细胞（AML）、1例淋巴瘤性白血病、2例骨髓增生异常综合征转AML,Kaplan-Meier生存计算2年无病生存率为52.5%.结论 G-CSF动员外周血干细胞输注预防单倍型HSCT后白血病复发,效果显著,安全性较好.Objective To explore the preventative effect of donor peripheral blood stem cell （PBSC） infusion mobilized by granulocyte colony-stimulating factor （G-CSF） for the relapsing patients with leukemia after haplotype hematopoietic stem cell transplantation （ HSCT） , as well as its therapeutic effect and safety. Methods G-CSF was given at 5-10 μg · kg-1 · d-1 to donor and PBSCs were obtained on day 5 and frozen and allotted for storing. PBSC infusion was given to all the 20 patients on day 90 after HSCT,and the second treatment was given to 4 patients on day 30 after the first infusion. The occurrence of graftversus-host disease （ GVHD） , relapse rate of high risk leukemia and long-term survival were evaluat after PBSC infusion. Results A total of 19 patients had acute GVHD after PBSC infusion for a median of 25 （12-60） months, 4 of them were ≥ degree Ⅲ. The cumulative incidence rate was 22.9%, and all of them accepted PBSC infusion twice. Thirteen patients had assessable chronic GVHD, 10 of them were restricted,and no one died of it. Nine patients died of relapse of leukemia. The remaining 11 patients survived leukemia free, including 4 with chronic myelogenous leukemia, 4 with acute myeloid leukemia （AML） , 1 with lymphoma-leukemia and 2 with myelodysplastic syndrome-AML （MDS-AML）. Kaplan-Meier analysis showed the disease free survival rate of 2-year was 52. 5%. Conclusion The prophylactic donor PBSC infusion mobilizing with G-CSF is effective, safe and feasible for the relapse of leukemia.

关 键 词：外周血干细胞移植 白血病 复发 粒细胞集落刺激因子 单倍型移植 

分 类 号：R733.7[医药卫生—肿瘤]